financetom
Business
financetom
/
Business
/
Mesa Air Group to Merge With Republic Airways in All-Stock Transaction
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mesa Air Group to Merge With Republic Airways in All-Stock Transaction
Apr 7, 2025 4:50 AM

07:30 AM EDT, 04/07/2025 (MT Newswires) -- Mesa Air Group Inc ( MESA ) and Republic Airways Holdings said Monday that they have entered into a definitive agreement to merge into one regional airline company in an all-stock transaction.

Financial terms of the transaction were not disclosed.

Upon closing, the combined company will be renamed Republic Airways Holdings, led by Republic's executive leadership team, and is expected to remain Nasdaq-listed under the new ticker symbol "RJET".

Upon closing, Republic shareholders will own 88% of the combined company's common shares, while Mesa ( MESA ) shareholders will own a minimum of 6% or maximum of 12% depending upon the achievement of certain pre-closing criteria.

The transaction has been unanimously approved by the boards of directors of both companies and is expected to close in either late Q3 or early Q4.

Republic will continue to support American Airlines, Delta Air Lines, and United Airlines under its existing capacity purchase agreements, and Mesa's ( MESA ) operations will support United Airlines under a new 10-year agreement as a result of this transaction.

Mesa ( MESA ), Republic, and United Airlines also entered a three-party agreement under which Mesa ( MESA ) will take actions to dispose of certain assets, extinguish certain liabilities and effectuate certain related transactions.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Target May Tighten 2025 Outlook as Q3 Comps Stay Weak, Oppenheimer Says
Target May Tighten 2025 Outlook as Q3 Comps Stay Weak, Oppenheimer Says
Nov 17, 2025
02:46 PM EST, 11/17/2025 (MT Newswires) -- Target ( TGT ) is likely to post soft Q3 on Wednesday with comparable sales down about 2% and could narrow its fiscal 2025 earnings per share guidance toward the low end of its $7 to $9 range, Oppenheimer said Monday in a pre-results report. Oppenheimer said it added conservatism to its Q4...
Liberty Defense Up Near 14% On Contract Win for Multiple HEXWAVE Walkthrough Screening Systems From a U.S. State Capitol Complex
Liberty Defense Up Near 14% On Contract Win for Multiple HEXWAVE Walkthrough Screening Systems From a U.S. State Capitol Complex
Nov 17, 2025
03:04 PM EST, 11/17/2025 (MT Newswires) -- Liberty Defense Holdings ( LDDFF ) shares were up near 14% on Monday after it received a competitive bid award for three HEXWAVE walkthrough screening systems at a U.S. State Capitol complex in the Northeast. The company said the systems will support security screening for officials, employees, and visitors across two high-traffic buildings....
Jones Lang LaSalle Offers Steady Growth Outlook, UBS Says
Jones Lang LaSalle Offers Steady Growth Outlook, UBS Says
Nov 17, 2025
02:58 PM EST, 11/17/2025 (MT Newswires) -- Jones Lang LaSalle ( JLL ) is set to benefit from improving industry tailwinds amid attractive valuation after its Q3 results, UBS Securities said in a Sunday note. The report pointed to an outlook downgrade for its Real Estate Management Services segment for the next several quarters while Q3 margin expansion disappointed, similar...
Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer
Jazz Pharmaceuticals Stock Rallies On Positive Phase 3 Trial Results for Ziihera In Advanced Gastroesophageal Cancer
Nov 17, 2025
Jazz Pharmaceuticals Plc ( JAZZ ) shares are popping on Monday following the company’s positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). What Happened: When compared to the control group that received trastuzumab...
Copyright 2023-2026 - www.financetom.com All Rights Reserved